The expression of AR, GATA3, ESR2, GBX2, KRT16, MMP28, and WNT11 in residual disease establishes a risk prediction for a three-year RFS, with 76.9% in the low risk patient category (those with “luminal-like” genes as AR or GATA3) presenting survival versus 25% of the patients included in the high risk group (those tumors characterized by expression of cancer stem cell markers as KRT16, WNT11, or MMP28). Here, KRT16 is linked to cancer.